Skip to content
DE

Does chromium picolinate reduce cravings and blood sugar?

Clinical review pending

Chromium picolinate may slightly affect blood sugar levels. How solid the studies on insulin resistance, cravings and weight loss really are.

Editorial draft. The medical claims and source attributions of the original text have not yet been independently checked; the text has been read in full and copyedited. Clinical sign-off is still pending.

Chromium picolinate is a chelated trace mineral supplement that has been studied mainly for its effect on blood sugar. Meta-analyses show a slight reduction in fasting glucose and HbA1c in insulin-resistant populations, but the effect depends on each person’s starting conditions and is clinically small. In its qualified health claim, the FDA describes the evidence on insulin resistance as “highly uncertain.” Weight-loss claims have been formally challenged by the FTC.

What chromium picolinate is

Chromium picolinate is a supplemental form of trivalent chromium. It consists of chromium(III) chelated with three molecules of picolinic acid. The picolinate chelation is meant to improve oral absorption compared with inorganic chromium salts. It is the most studied form of chromium supplement when it comes to effects on blood sugar.

Trivalent chromium is the biologically relevant oxidation state, and it is the one present in this supplement. Hexavalent chromium is an industrial toxin: a completely different chemical species that has no relevance here. Trivalent chromium has been studied for its role in insulin signaling for decades, but the exact mechanism is still actively debated. Source

Chemistry and structure

Chromium picolinate is a coordination complex: one chromium(III) ion bound to three picolinic acid ligands. Picolinic acid is a naturally occurring metabolite of tryptophan. Chelation keeps chromium soluble in the gut, which presumably improves absorption compared with inorganic chromium salts such as chromium chloride. At the cellular level, chromium picolinate affects the glucose transporters of fat cells (adipocytes). The exact bioactive species in vivo, however, has not been fully worked out. Chromium may separate from the picolinate ligand during or after absorption, which means the picolinate itself may not be the active component in tissue. Source

From glucose tolerance factor to picolinate

Chromium was first identified in the 1950s and 1960s as a component of the “glucose tolerance factor” in brewer’s yeast. Chromium picolinate emerged as a supplement form in its own right in the 1980s. In 2005 the FDA issued a qualified health claim specifically for chromium picolinate and insulin resistance: a claim that must carry the wording “highly uncertain.” Separately, the FTC challenged weight-loss marketing claims for chromium picolinate in the 1990s and 2000s. Meta-analyses of chromium picolinate and body weight found the effects too small to be clinically meaningful. The assessments of both agencies matter for putting the evidence in context. Source

How chromium picolinate is supposed to work

The main mechanism under discussion is an amplification of insulin receptor signaling through a chromium-binding protein called chromodulin (a small chromium-carrying peptide in insulin-responsive cells). According to this hypothesis, if insulin signaling already works well, there is less room for any extra boost. This is not a confirmed mechanism. It is a well-characterized hypothesis supported by biochemical data, but it has not yet been proven in controlled human trials.

Chromodulin and insulin signaling

The chromodulin hypothesis proposes that chromium is bound by a low-molecular-weight binding substance (LMWCr, or chromodulin) inside insulin-responsive cells. Once loaded with chromium, chromodulin is thought to boost the activity of the insulin receptor’s tyrosine kinase. That would amplify the downstream signaling cascade that moves glucose transporters to the cell surface. The chromium-binding properties of chromodulin have been characterized in detail. At the cellular level, chromium picolinate has been shown to influence GLUT4 translocation in fat cells: the same transport system that insulin activates. The available data fit the LMWCr hypothesis but do not prove it. The mechanism is plausible and biochemically coherent. It is not confirmed proof of an effect in humans. Source 1 Source 2 Source 3 Source 4

Bioavailability of chromium picolinate

Oral chromium absorption is low for every form (roughly 0.4–2.5% for inorganic salts). Picolinate chelation improves this somewhat, though exact human bioavailability figures vary from study to study. After absorption, chromium is distributed to the liver, spleen, kidneys and bone. It is excreted mainly in urine. The half-life and tissue retention of supplemental doses are not well characterized in humans. Typical doses tested in clinical trials range from 200 to 1,000 µg per day for 8 to 24 weeks. Higher doses have been tested in studies of PCOS and binge eating. PCOS trials used doses at the upper end of this range. Trial protocols usually call for taking the dose with food, because food affects chromium absorption. Source

How well supported are the claimed benefits?

Claims about chromium picolinate cover four areas, each with evidence of different strength: blood sugar control in type 2 diabetes (moderate), insulin sensitivity in PCOS (limited), carbohydrate cravings and binge eating (limited), and clinically meaningful weight loss (anecdotal, and challenged by the FTC).

Chromium picolinate slightly improves blood sugar control in type 2 diabetes: moderate evidence

A large meta-analysis found that chromium supplementation slightly lowered fasting glucose and HbA1c in type 2 diabetes. An earlier meta-analysis confirmed significant but heterogeneous effects on the same endpoints. A randomized controlled trial showed that chromium picolinate increased insulin sensitivity in type 2 diabetes. The key limitation: clinical response depends heavily on starting conditions, especially insulin sensitivity at the start of the study. Baseline insulin sensitivity, body weight and HbA1c help predict who responds. Insulin-resistant populations show consistent, modest improvements. Healthy adults with normal glucose metabolism do not. Source 1 Source 2 Source 3 Source 4

Chromium picolinate improves insulin sensitivity in PCOS: limited evidence

One RCT found reduced insulin resistance in women with PCOS who took chromium picolinate. A separate RCT reported improvements in insulin sensitivity and lipid markers in the same population. A PCOS-specific systematic review and meta-analysis found moderate effect sizes across the available studies. The individual trials are small. They point to an effect on PCOS-related insulin resistance but do not yet settle the question. Source 1 Source 2 Source 3

Chromium picolinate reduces carbohydrate cravings or binge eating: limited evidence

A placebo-controlled trial in atypical depression found that chromium slightly reduced carbohydrate cravings. A pilot RCT in binge eating disorder found small effects of chromium picolinate on eating behavior. A separate study observed a slight reduction in food intake in overweight women. In every case the data come from small or pilot studies. The proposed mechanism (steadier glucose dampens appetite signaling) is plausible but has not been clinically validated. Source 1 Source 2 Source 3

Chromium picolinate leads to clinically meaningful weight loss: anecdotal reports only; marketing challenged by the FTC

A systematic review found only small, clinically modest weight reductions from chromium supplementation in people with overweight. An earlier meta-analysis likewise questioned the clinical relevance of any weight effect. A controlled study in wrestlers found no effect on body composition or muscle performance. A critical review concluded that the evidence is not sufficient to support weight-loss marketing. The FTC has formally challenged weight-loss marketing claims for chromium picolinate. Clinically meaningful weight loss has not been shown. Source 1 Source 2 Source 3 Source 4

It has not been shown that chromium picolinate adequately treats or cures type 2 diabetes, produces clinically meaningful weight loss, or improves body composition in healthy adults. The FTC has challenged weight-loss advertising of this kind. Evidence of reduced cravings comes only from small pilot studies. Chromium picolinate is not a substitute for medically necessary glucose-lowering medication.

Chromium picolinate compared with other forms of chromium

Among the chromium supplements on the market, chromium picolinate has by far the largest body of clinical trial data. For other forms (chromium polynicotinate, GTF chromium and chromium chloride) there is much less data on effects in humans. Head-to-head human comparisons of bioavailability and efficacy are scarce.

Chromium picolinate is standardized to the picolinate chelate, with typical capsule strengths of 200–1,000 µg. Chromium polynicotinate chelates chromium with niacinamide and is marketed with similar absorption claims, but fewer outcome studies exist. GTF chromium is derived from brewer’s yeast; whether the “glucose tolerance factor” can be characterized as a defined molecular entity remains disputed today. Third-party testing programs (USP, NSF International and ConsumerLab) independently check label accuracy and heavy metal contamination, which matters for the whole category of chromium supplements. Case reports of DNA damage linked specifically to the picolinate form have not led to regulatory action, but they have to be factored into any safety assessment. Without supporting comparative data, no single form can be considered superior; the exact form listed on the certificate of analysis and third-party certification are the practical quality checkpoints. Source

Regulatory status: as of May 2026

In the United States, chromium picolinate is legally marketed as a dietary supplement under DSHEA (the Dietary Supplement Health and Education Act). That legal framework governs its sale as a supplement there. No FDA approval is required before it goes on the market.

In 2005 the FDA issued a qualified health claim for chromium picolinate. The permitted wording can be paraphrased as follows: “One small study suggests that chromium picolinate may reduce the risk of insulin resistance, and therefore possibly the risk of type 2 diabetes. FDA concludes, however, that the existence of such a relationship between chromium picolinate and either insulin resistance or type 2 diabetes is highly uncertain.” That phrase (“highly uncertain”) is the FDA’s own characterization of the evidence. It is the regulator’s assessment of the data, not merely a cautious add-on to the marketing.

Separately, the FTC has challenged weight-loss marketing claims for chromium picolinate. The source article refers to documented enforcement actions on this point. The weight-loss evidence has been reviewed independently and found insufficient to back marketing claims. According to the source article, as of May 2026 chromium picolinate is not on the World Anti-Doping Agency (WADA) Prohibited List. Regulators view the blood sugar claim as weakly supported and the weight-loss claim as unsupported. Source

Safety, side effects and drug interactions

Short-term safety at typical supplemental doses of 200–1,000 µg per day is fairly well described in clinical trials, and this range appears on most labels. Case reports describing DNA damage and kidney effects at higher doses or with longer use have to be taken into account, especially for the picolinate form. Source

Reported side effects

The adverse events reported most often in studies are mild and uncommon: stomach and gut discomfort, headache and dizziness. Rare reports include heart palpitations. More serious case reports describe rhabdomyolysis and kidney and liver problems. These reports involve high doses or prolonged use. A safety review of the controversy specific to the picolinate form includes case reports of DNA damage that have not been seen to the same degree with other forms of chromium. This picolinate-specific signal has not been confirmed in controlled trials at typical supplemental doses, but it is relevant to the safety assessment. A dose-response meta-analysis found no significant adverse effects on blood pressure, BMI or liver enzymes at the doses studied in populations with diabetes. Source 1 Source 2

Drug interactions

  • Insulin and sulfonylureas (moderate). Additional risk of hypoglycemia in people with type 2 diabetes; the combination should be cleared with a doctor beforehand.

  • Levothyroxine (minor). Theoretical chelation that reduces thyroid hormone absorption; the source article recommends spacing doses 2–4 hours apart when both are taken.

  • NSAIDs, chronic use (minor). Theoretical effect on chromium absorption and kidney excretion; the data are thin.

  • Other glucose-lowering supplements, berberine, alpha-lipoic acid (minor). An additive effect on blood sugar is plausible; monitoring is needed when several are used together.

Pregnancy, breastfeeding and organ function

Dietary chromium needs rise during pregnancy, but supplemental chromium picolinate is generally avoided because there are no controlled human safety data at supplemental doses. Case reports describe liver effects at higher doses; people with existing liver disease should get medical advice before use. Chromium is excreted by the kidneys, so existing kidney impairment substantially changes the balance of benefits and risks. Supplemental doses have not been adequately studied in children.

Who should avoid chromium picolinate?

Several groups have documented reasons not to take chromium picolinate without medical supervision: pregnancy and breastfeeding (no safety data), people on insulin or sulfonylurea therapy (additional hypoglycemia), active liver or kidney disease, people whose main goal is weight loss, and children. These cautions are based on described interactions and gaps in the data.

  • Pregnant or breastfeeding people: no controlled human safety data at supplemental doses.

  • People with type 1 or type 2 diabetes who take insulin or sulfonylureas without medical supervision: additional risk of hypoglycemia.

  • Active liver disease: case reports describe liver effects at higher doses.

  • Active kidney disease: chromium is excreted by the kidneys; reduced function changes the balance of benefits and risks.

  • Anyone whose main interest is weight loss: the evidence does not support this use, and the FTC has challenged the marketing.

  • Children: there are not enough data on supplemental doses in children.

If any of these apply, talk to a doctor before taking it. Bring your complete medication list and any lab results you have.

Picolinate, polynicotinate and GTF side by side

When choosing, what matters most is which form of chromium has actually been studied. Chromium picolinate dominates the published literature by a wide margin.

  • Source / chemistry. Picolinate: Cr(III) chelated with picolinic acid. Polynicotinate: Cr(III) chelated with niacinamide. GTF: brewer’s yeast extract; its modern molecular characterization remains disputed.

  • Bioavailability. Picolinate: improved compared with inorganic salts; absolute oral bioavailability is still low. Polynicotinate: similar absorption claims; less supporting data. GTF: higher bioavailability claimed; published human data scarce.

  • Best-supported effects. Picolinate: a meta-analysis in type 2 diabetes found slight reductions in fasting glucose and HbA1c; an RCT showed increased insulin sensitivity in type 2 diabetes; PCOS RCTs. Polynicotinate/GTF: limited human RCT evidence. Source 1 Source 2

  • Dose range studied. Picolinate: 200–1,000 µg/day. Polynicotinate: 200–400 µg/day in available studies. GTF: variable; brewer’s yeast extract is not standardized.

  • Key safety differences. Picolinate: case reports of DNA damage specific to the picolinate form. Polynicotinate/GTF: no comparable signal, but also fewer long-term human data. Source

  • Cost (relative). Picolinate: $. Polynicotinate: $–$$. GTF: $$.

  • Regulatory status. Picolinate: FDA qualified health claim with mandatory “highly uncertain” wording; weight-loss advertising challenged by the FTC. Polynicotinate/GTF: same DSHEA status; no equivalent FDA qualified health claim.

For someone who mainly wants the best-studied form, the one with the FDA qualified health claim, picolinate has the stronger evidence base. For someone mainly worried about the DNA damage signal tied to the picolinate form, polynicotinate is a possible alternative, though it has far less clinical outcome data. Neither option answers the basic question of whether chromium supplementation does anything useful for a particular person. As the measures for answering that question, the source article names HbA1c, fasting insulin and HOMA-IR, measured at the start and again after 12 weeks, at the same lab, under the same morning conditions, before other variables change.

Which measurements are suggested for tracking

A subjective feeling of more energy or fewer cravings is not, on its own, reliable proof that something works. The source article recommends comparable lab tests on day 0 and in week 12, each time at the same lab and under the same fasted morning conditions.

  • HbA1c: average blood sugar exposure over three months; the endpoint that changed slightly in the type 2 diabetes meta-analysis, and the primary measure of chromium’s effect on blood sugar. Source

  • Fasting glucose: current blood sugar level; responds faster than HbA1c, typically within 4–8 weeks of an intervention.

  • Fasting insulin: combined with fasting glucose, it gives HOMA-IR, the insulin sensitivity surrogate used in the main RCT and in all the PCOS trials. Source

  • LDL-C: a systematic review found slight reductions in total cholesterol and triglycerides with chromium; LDL-C is the standard cardiovascular lipid endpoint. Source

  • ApoB: the number of atherogenic particles; a more direct measure of cardiovascular risk than LDL-C alone, especially in insulin-resistant populations.

Getting these baseline values before starting chromium picolinate or any new supplement gives you objective reference points that make any later change interpretable. Without a baseline, a response cannot be told apart from regression to the mean or a placebo effect.

When symptoms need a medical workup

If the reason for reaching for chromium picolinate is symptoms (increased thirst, frequent urination, unexplained weight change, or fatigue with patterns of reactive hypoglycemia), those symptoms should be checked by a primary care doctor. The source article mentions a medical examination with HbA1c, fasting glucose, fasting insulin and blood lipids. Self-treatment with supplements does not replace that workup. If food cravings or binge eating are what prompted the search, a possible eating disorder should be assessed by a doctor rather than experimented on with supplements. A doctor is the right place to start.

The evidence for supplements aimed at blood sugar remains mixed and disputed. Baseline measurements make a clear, traceable assessment possible, whether or not chromium picolinate is used later. Source

Frequently asked questions

What is chromium picolinate?

Chromium picolinate is a supplemental form of the trace mineral chromium, chelated with picolinic acid to aid absorption. It is marketed to support blood sugar levels and insulin sensitivity and to reduce carbohydrate cravings. The clinical evidence is mixed and the effect sizes are modest.

What is chromium picolinate used for?

Chromium picolinate has mainly been studied in populations with insulin resistance and type 2 diabetes, where a meta-analysis showed slight improvements in fasting glucose and HbA1c. It has also been looked at in small studies on carbohydrate cravings and eating behavior; the evidence there remains preliminary. The FTC has challenged weight-loss advertising claims. The FDA-permitted health claim for chromium picolinate refers specifically to insulin resistance, not weight loss, and includes “highly uncertain” wording. Source 1 Source 2

What does chromium picolinate do in the body?

Chromium is a trace mineral thought to enhance insulin action through a low-molecular-weight chromium-binding substance called chromodulin, or LMWCr. The exact mechanism is debated, and researchers urge caution about the chromodulin hypothesis. Evidence at the cellular level is consistent with enhanced insulin signaling, although the evidence on clinical outcomes in humans is rather mixed. Source 1 Source 2 Source 3

Is chromium picolinate a vitamin, a mineral or an herbal product?

Chromium is a trace mineral (an essential trace element); chromium picolinate is its picolinate-chelated supplement form, not a vitamin or herbal product in its own right. In the US it is sold as a dietary supplement under DSHEA and has an FDA-permitted health claim on insulin resistance.

Where does chromium picolinate come from?

Dietary chromium occurs in trace amounts in broccoli, grape juice, whole grains, brewer’s yeast and meat. Supplemental chromium picolinate is made by chelating chromium(III) with picolinic acid, mostly through chemical synthesis. The picolinate complex is meant to improve oral absorption; typical capsule strengths range from 200 to 1,000 µg.

Are there alternatives to chromium picolinate?

Yes, there are alternatives, although chromium picolinate is still the most studied supplement form. Other forms include chromium polynicotinate (chromium nicotinate), GTF chromium (glucose tolerance factor; a brewer’s yeast extract) and chromium chloride. There are, however, few direct human data comparing the bioavailability and clinical outcomes of these forms.

Does chromium picolinate really work?

Research suggests that chromium picolinate may support insulin sensitivity in insulin-resistant populations, with meta-analyses showing slight improvements in fasting glucose and HbA1c in type 2 diabetes. In healthy populations, however, the effects are inconsistent, because the response depends on baseline insulin sensitivity, body weight and HbA1c. Weight-loss claims lack sufficient evidence and have been challenged by regulators. Source 1 Source 2

Is chromium picolinate available as a supplement?

Yes. In the US, chromium picolinate is legally marketed as a dietary supplement under DSHEA. The FDA has a permitted qualified health claim on chromium picolinate and insulin resistance, although the FDA acknowledges that the relationship is “highly uncertain.” According to the source article, as of May 2026 the FTC has challenged weight-loss advertising claims, and only FDA-permitted claims are allowed.

Sources and literature from the original text

  • Vincent JB (2000). The biochemistry of chromium. The Journal of nutrition, 130(4), 715-8. https://doi.org/10.1093/jn/130.4.715

  • Pattar GR, Tackett L, Liu P, Elmendorf JS (2006). Chromium picolinate positively influences the glucose transporter system via affecting cholesterol homeostasis in adipocytes cultured under hyperglycemic diabetic conditions. Mutation research, 610(1-2), 93-100. https://doi.org/10.1016/j.mrgentox.2006.06.018

  • Pittler MH, Stevinson C, Ernst E (2003). Chromium picolinate for reducing body weight: meta-analysis of randomized trials. International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity, 27(4), 522-9. https://doi.org/10.1038/sj.ijo.0802262

  • Chen Y, Watson HM, Gao J, Sinha SH, Cassady CJ, Vincent JB (2011). Characterization of the organic component of low-molecular-weight chromium-binding substance and its binding of chromium. The Journal of nutrition, 141(7), 1225-32. https://doi.org/10.3945/jn.111.139147

  • Vincent JB (2004). Recent advances in the nutritional biochemistry of trivalent chromium. The Proceedings of the Nutrition Society, 63(1), 41-7. https://doi.org/10.1079/PNS2003315

  • Jamilian M, Asemi Z (2015). Chromium Supplementation and the Effects on Metabolic Status in Women with Polycystic Ovary Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial. Annals of nutrition & metabolism, 67(1), 42-8. https://doi.org/10.1159/000438465

  • Asbaghi O, Fatemeh N, Mahnaz RK, Ehsan G, Elham E, Behzad N, Damoon AL, Amirmansour AN (2020). Effects of chromium supplementation on glycemic control in patients with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. Pharmacological research, 161, 105098. https://doi.org/10.1016/j.phrs.2020.105098

  • Yin RV, Phung OJ (2015). Effect of chromium supplementation on glycated hemoglobin and fasting plasma glucose in patients with diabetes mellitus. Nutrition journal, 14, 14. https://doi.org/10.1186/1475-2891-14-14

  • Martin J, Wang ZQ, Zhang XH, Wachtel D, Volaufova J, Matthews DE, Cefalu WT (2006). Chromium picolinate supplementation attenuates body weight gain and increases insulin sensitivity in subjects with type 2 diabetes. Diabetes care, 29(8), 1826-32. https://doi.org/10.2337/dc06-0254

  • Wang ZQ, Qin J, Martin J, Zhang XH, Sereda O, Anderson RA, Pinsonat P, Cefalu WT (2007). Phenotype of subjects with type 2 diabetes mellitus may determine clinical response to chromium supplementation. Metabolism: clinical and experimental, 56(12), 1652-5. https://doi.org/10.1016/j.metabol.2007.07.007

  • Ashoush S, Abou-Gamrah A, Bayoumy H, Othman N (2016). Chromium picolinate reduces insulin resistance in polycystic ovary syndrome: Randomized controlled trial. The journal of obstetrics and gynaecology research, 42(3), 279-85. https://doi.org/10.1111/jog.12907

  • Fazelian S, Rouhani MH, Bank SS, Amani R (2017). Chromium supplementation and polycystic ovary syndrome: A systematic review and meta-analysis. Journal of trace elements in medicine and biology : organ of the Society for Minerals and Trace Elements (GMS), 42, 92-96. https://doi.org/10.1016/j.jtemb.2017.04.008

  • Davidson JR, Abraham K, Connor KM, McLeod MN (2003). Effectiveness of chromium in atypical depression: a placebo-controlled trial. Biological psychiatry, 53(3), 261-4. https://doi.org/10.1016/s0006-3223(02)01500-7

  • Brownley KA, Von Holle A, Hamer RM, La Via M, Bulik CM (2013). A double-blind, randomized pilot trial of chromium picolinate for binge eating disorder: results of the Binge Eating and Chromium (BEACh) study. Journal of psychosomatic research, 75(1), 36-42. https://doi.org/10.1016/j.jpsychores.2013.03.092

  • Anton SD, Morrison CD, Cefalu WT, Martin CK, Coulon S, Geiselman P, Han H, White CL, Williamson DA (2008). Effects of chromium picolinate on food intake and satiety. Diabetes technology & therapeutics, 10(5), 405-12. https://doi.org/10.1089/dia.2007.0292

  • Onakpoya I, Posadzki P, Ernst E (2013). Chromium supplementation in overweight and obesity: a systematic review and meta-analysis of randomized clinical trials. Obesity reviews : an official journal of the International Association for the Study of Obesity, 14(6), 496-507. https://doi.org/10.1111/obr.12026

  • Walker LS, Bemben MG, Bemben DA, Knehans AW (1998). Chromium picolinate effects on body composition and muscular performance in wrestlers. Medicine and science in sports and exercise, 30(12), 1730-7. https://doi.org/10.1097/00005768-199812000-00012

  • Wharton S, Bonder R, Jeffery A, Christensen RAG (2020). The safety and effectiveness of commonly-marketed natural supplements for weight loss in populations with obesity: A critical review of the literature from 2006 to 2016. Critical reviews in food science and nutrition, 60(10), 1614-1630. https://doi.org/10.1080/10408398.2019.1584873

  • Golubnitschaja O, Yeghiazaryan K (2012). Opinion controversy to chromium picolinate therapy’s safety and efficacy: ignoring ‘anecdotes’ of case reports or recognising individual risks and new guidelines urgency to introduce innovation by predictive diagnostics?. The EPMA journal, 3(1), 11. https://doi.org/10.1186/1878-5085-3-11

  • Asbaghi O, Naeini F, Ashtary-Larky D, Kaviani M, Rezaei Kelishadi M, Eslampour E, Moradi S, Mirzadeh E, Clark CCT, Naeini AA (2021). Effects of chromium supplementation on blood pressure, body mass index, liver function enzymes and malondialdehyde in patients with type 2 diabetes: A systematic review and dose-response meta-analysis of randomized controlled trials. Complementary therapies in medicine, 60, 102755. https://doi.org/10.1016/j.ctim.2021.102755

  • Tarrahi MJ, Tarrahi MA, Rafiee M, Mansourian M (2021). The effects of chromium supplementation on lipidprofile in humans: A systematic review and meta-analysis ofrandomized controlled trials. Pharmacological research, 164, 105308. https://doi.org/10.1016/j.phrs.2020.105308

  • Hekmat-Ardakani A, Morshed-Behbahani B, Rahimi-Ardabili H, Ayati MH, Namazi N (2023). The effects of dietary supplements and natural products targeting glucose levels: an overview. Critical reviews in food science and nutrition, 63(23), 6138-6167. https://doi.org/10.1080/10408398.2022.2028716

Origin and editorial review status

Translated and prepared for Nutrient Desk from the original article. Promotional membership, newsletter and lab test offers have been removed. The bibliography is kept in its original form so each entry can be identified unambiguously. Figures and source references were carried over; which evidence supports which individual claim must be checked before publication. This draft is not cleared for indexing.